Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy.

Elizabeth Jaffee is an Oncologist in Baltimore, Maryland. Dr. Jaffee is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Kelly Lafaro, MD, MPH, is a general surgeon with a specialty in gastrointestinal surgical oncology and hepatobiliary surgery. She is part of the Johns Hopkins Kimmel Cancer Center. Dr. Lafaro earned her medical degree from Tulane University School of Medicine and completed her residency at New York-Presbyterian/Columbia University Irving Medical Center. Her fellowship in complex general surgical oncology was completed at City of Hope National Medical Center. Dr. Lafaro’s expertise includes pancreatic adenocarcinoma, neuroendocrine tumors, minimally invasive pancreatic and liver surgeries, and colorectal liver metastases. In addition to her clinical experience, Dr. Lafaro is published in the field of liver and pancreatic cancer. She is interested in the improvement of surgical and post-surgical outcomes. Dr. Lafaro is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreatectomy, and Pancreaticoduodenectomy.

Dr. Elliot K. Fishman is a Professor in the Johns Hopkins Medicine Department Radiology and Radiological Science, Department of Oncology and Department of Surgery. He serves as a member of the Johns Hopkins Kimmel Cancer Center. His clinical and research interests focus on medical imaging with specific emphasis on three-dimensional (3D) imaging and computed tomography (CT). Dr. Fishman received his B.S. in 1973 and M.D. in 1977 from the University of Maryland. After a residency at Sinai Hospital in Baltimore, he completed a fellowship in CT at Johns Hopkins in 1980 and joined the Johns Hopkins faculty in 1981 as an Assistant Professor. In 1986, he became Associate Professor and, in 1991, Professor of Radiology and Oncology. He is a leader in the development of 3D imaging and rendering, including its impacts on and uses in patient care and management. He was involved from the beginning in the development of 3D imaging through his work with Pixar, which was a spin-off from LucasFilms in San Rafael, California. Over the last 25 years, Dr. Fishman continued to help develop 3D imaging and has been a leader in the development of interactive 3D rendering. His team is consistently at the forefront of research and development of new visualization and post-processing techniques and technologies. Dr. Fishman's extensive body of work in CT has resulted in over 1,000 peer-reviewed publications, and he is the author or co-author of 10 textbooks. He is the recipient of three prestigious Aunt Minnie Awards, honoring his outstanding contributions as both an educator and researcher. In 2007, he was named by Medical Imaging Magazine as the Top Radiologist in the Nation. He is a member of editorial boards for more than 35 journals, an active member of several professional radiology associations and is a past-president of the Society of Body CT/MR. Dr. Fishman is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Cavernous Lymphangioma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Linda Chi Hang Chu is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her clinical expertise includes body CT, MRI and US. Her research interests include abdominal imaging, cancer imaging, radiomics, and artificial intelligence. Dr. Chu graduated from the University of Toronto in 2003 and was awarded the Governor General's Silver Medal, the highest academic achievement from the undergraduate program. She earned her medical degree as a member of AOA and phi beta kappa from Johns Hopkins University in Baltimore, MD in 2007. She completed her Diagnostic Radiology residency and body MRI fellowship at Johns Hopkins Hospital. Dr. Chu joined the Johns Hopkins faculty in 2013. Dr. Chu is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gallbladder Removal.

Dr. Narang is an Assistant Professor in the Johns Hopkins Department of Radiation Oncology & Molecular Sciences. A former chief resident in the department, Dr. Narang now specializes in radiation treatment for gastrointestinal malignancies, including pancreatic cancer, colorectal cancer, hepatobiliary malignancies, and gastric cancer. Dr. Narang has an interest in expanding multi-disciplinary care for patients with gastrointestinal malignancies. Make A Gift. Dr. Narang is rated as an Advanced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Won Jin Ho is a physician-scientist at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins who focuses on cancer immunology and tumor microenvironment research. Dr. Ho received his BS and MS in Biomedical Engineering from University of California, Los Angeles, and his MD from Wayne State University School of Medicine. Dr. Ho completed a research track internal medicine residency as an NIH F32 postdoctoral fellow at Case Western Reserve University and subsequently completed a medical oncology fellowship at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as the recipient of ASCO Young Investigator Award and AACR Immuno-Oncology Fellowship. Dr. Ho's overarching research interest is to develop novel immunotherapeutic strategies even against immune-resistant cancers by first understanding the immune responses to current therapeutics. Dr. Ho focuses on determining the systemic and in situ changes by leveraging cutting-edge technologies. With his expertise in mass cytometry, Dr. Ho is co-leading many of the systemic and spatial immune profiling efforts at Johns Hopkins. Dr. Ho also is developing novel small-molecule cancer therapeutics and methodologies for translational discovery. Dr. Ho is rated as an Advanced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Liver Cancer, and Hepato-Pancreato-Biliary Surgery.

Christopher Shubert, M.D., M.H.A., is a general surgeon with specialty training and interests in hepato-pancreato-biliary (HPB) surgery. He is a member of the Division of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology at The Johns Hopkins Hospital. Dr. Shubert earned his medical degree from the University of Alabama School of Medicine and completed his general surgery residency at the Mayo Clinic in Rochester, Minnesota. He completed fellowship training in HPB surgical oncology and abdominal organ transplantation at the University of Toronto. In addition to his clinical experience, Dr. Shubert earned a Master's of Science in Healthcare Administration from the University of Alabama at Birmingham. Dr. Shubert's clinical interests include HPB surgery, resection of traditionally unresectable liver lesions, tumors involving the vena cava, and pancreas resections with vascular reconstruction. His research focus includes hepatobiliary and pancreatic malignancies, their respective treatments, perioperative management, and outcomes. Dr. Shubert is rated as an Advanced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Atif Zaheer is a Professor of Radiology and Radiological science at Johns Hopkins University School of Medicine, as well as the director of the Cross-Sectional Body Imaging Fellowship program. Dr. Zaheer practices at the Johns Hopkins Hospital in Baltimore, MD. Dr. Zaheer earned his medical degree from the Aga Khan University. He completed a residency in diagnostic radiology at Beth Israel Deaconess Medical Center/Harvard Medical School, followed by a fellowship in abdominal imaging and interventional radiology at Brigham and Women’s Hospital/Harvard Medical School. Dr. Zaheer is also the medical director of the e-Radiology learning program at Johns Hopkins, which provides radiology residents and practicing radiologists around the world with a lecture series designed to address core knowledge of normal anatomy, pathology and background physics required for successful practice of the field. Dr. Zaheer is clinically active in cross-sectional imaging of the body using CT, MRI and Ultrasound and is also involved in multidisciplinary conferences for pancreas, liver and rectal cancer imaging. His research interests include imaging of tumors and inflammatory disorders of the pancreas and is considered a leader in pancreatic imaging. He is the associate editor of the journal Abdominal Radiology and actively participates in clinical trials, publishes scientific articles, authors books on pancreatic and gastrointestinal imaging, and gives talks at national and international conferences. Dr. Zaheer is rated as an Advanced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Muscle Invasive Bladder Cancer, Pancreatic Ductal Adenocarcinoma, Pancreas Divisum, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Satomi Kawamoto is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. She specializes in computed tomography (CT), ultrasound, and image-guided biopsy. Dr. Kawamoto received her M.D. from Gunma University in Gunma, Japan, and subsequently completed two residencies, one in internal medicine at St. Luke’s International Hospital in Tokyo, and a second in diagnostic radiology at Johns Hopkins. She received a postdoctoral fellowship in cross-sectional imaging at Johns Hopkins, and then joined the Johns Hopkins faculty. Dr. Kawamoto’s research focuses on body CT and biopsy, particularly imaging of the genitourinary and gastrointestinal systems. Dr. Kawamoto is rated as an Advanced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Neuroendocrine Tumor, Muscle Invasive Bladder Cancer, Cavernous Lymphangioma, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

Norman G. Nicolson, M.D., M.H.S., is an Assistant Professor of Surgery at the Johns Hopkins University School of Medicine and a surgical oncologist within the Division of HPB & Gastrointestinal Surgical Oncology. Dr. Nicolson completed his complex general surgical oncology clinical fellowship training and an NIH-funded T32 research fellowship at Johns Hopkins prior to joining the surgical faculty. Prior to this, he completed his undergraduate work at Williams College and medical degree at Northwestern University, followed by internship and residency in general surgery at Yale New Haven Hospital with a Masters in Health Sciences and research fellowship at Yale University. Dr. Nicolson specializes in treating patients with gastric cancer, peritoneal surface malignancy, appendiceal neoplasms, retroperitoneal sarcoma, gastrointestinal neuroendocrine and stromal tumors, and complex or recurrent tumors of the GI tract. He is trained in both minimally invasive and traditional open approaches to treating these cancers, utilizing laparoscopic or robotic approaches when appropriate. He emphasizes the importance of multi-disciplinary care and patient-centered decision-making, working closely with colleagues in medical and radiation oncology, gastroenterology, and radiology to provide comprehensive personalized cancer care appropriate to each individual. Dr. Nicolson's translational research focuses on computational and bioinformatics approaches to high-dimensional sequencing data from human biospecimens to better understand tumor cell biomarker heterogeneity and the importance of the tumor-draining lymph node in tumor-immune cell interactions in gastrointestinal tumors. He is a member of several academic and clinical professional societies, including the American College of Surgeons, the Association for Academic Surgery, the American Society for Clinical Oncology, the American Association for Cancer Research, and the Society of Surgical Oncology. Dr. Nicolson is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Follicular Thyroid Cancer, Pancreaticoduodenectomy, and Thyroidectomy.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.

Eric Christenson is an Oncologist in Baltimore, Maryland. Dr. Christenson is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Cholangiocarcinoma (Bile Duct Cancer).

Marco Dal Molin, M.D., is a surgical oncologist that specializes in hepatobiliary, pancreatic and gastrointestinal surgical oncology at the Johns Hopkins Hospital. Dr. Dal Molin earned his medical degree at the University of Verona School of Medicine in Italy, followed by a general surgery residency at the University of Verona/Pancreas Institute. He completed a second general surgery residency at the University of Maryland in Baltimore, and a fellowship in Complex General Surgical Oncology at Johns Hopkins. Dr. Dal Molin received extensive postdoctoral research training at Johns Hopkins, including an NIH-funded T32 research fellowship prior to joining the surgical faculty. He specializes in the management of patients with pancreatic cancer, pancreatic cysts, as well as cancers of the liver, biliary tree and gastrointestinal tract. He is trained in traditional open and minimally invasive techniques to treating these cancers, using both laparoscopic and robotic approaches. Dr. Dal Molin’s research focuses on the development of liquid biopsies to improve the earlier detection and management of pancreatic cancer and pancreatic cysts. Another area of focus is the development of novel immunotherapies to treat pancreatic and hepatobiliary cancers. Dr. Molin is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.